Karen Lewis joins Clinsys as Vice President of Global Clinical Operations

Karen Lewis joins Clinsys as Vice President of Global Clinical Operations

BEDMINSTER, N.J.--(BUSINESS WIRE)--Clinsys Clinical Research, Inc.®, a therapeutically focused clinical research organization, today announced that Karen Lewis has joined the company as Vice President of Global Clinical Operations. Ms. Lewis brings more than 20 years of clinical research experience in multiple therapeutic areas including infectious disease, gastrointestinal diseases, cardiovascular, central nervous system, ophthalmology, dermatology and women's health.

In her role at Clinsys, Ms. Lewis will be responsible for the project management and field operations groups including training, development and growth initiatives. She will also work to develop the strategic direction, global integration and expansion of clinical operations for the company.

"Clinsys is a premier leader in the CRO industry, and I am honored to have the opportunity to join the talented individuals within this organization as Clinsys continues to provide quality service to its clients," stated Ms. Lewis.

Prior to joining Clinsys, Ms. Lewis held positions of increasing responsibility at PharmaNet, SFBC International, and Otsuka Maryland Research Institute, Inc. (formerly Otsuka America Pharmaceutical, Inc.) She has led many global initiatives and worked closely with business development and process improvement committees to implement operating efficiencies and strategic global programs resulting in increased effectiveness and winning study designs.

"The combination of Karen Lewis' expertise and experience make her an ideal addition to the Clinsys management team," stated Sri Mosur, CEO and President of Jubilant Drug Discovery and Development. "She brings not only a superb understanding of contract research but also has a very good perspective from the sponsor's side of the business. Karen will be able to provide excellent insight into our operational and business strategy as Clinsys strives to achieve highly efficient outcomes, optimizing and accelerating the drug development process of our collaborators worldwide."

A graduate of the University of North Carolina at Chapel Hill with a bachelor's degree in chemistry, Ms. Lewis received her masters of science in biotechnology from Johns Hopkins University. Ms. Lewis is an active member of several industry organizations and has authored or co-authored numerous publications on drug development.

About Clinsys Clinical Research, Inc.

Clinsys Clinical Research, Inc.®, is a therapeutically focused clinical research organization that provides pharmaceutical, biotechnology and medical device companies with a full range of clinical research services in support of Phase I-IV drug and device development. Clinsys has expertise in highly specialized therapeutic areas, including oncology, central nervous system, dermatology, respiratory and cardiovascular.

Clinsys, headquartered in Bedminster, New Jersey, with operations in Raleigh, North Carolina; Ottawa, Ontario; Noida and Bangalore, India and Düsseldorf, Germany, provides extensive clinical research services for Phase I-IV drug development, and operates a clinical pharmacology unit performing bioavailability and bioequivalence studies as well as bioanalytical sample analysis, clinical laboratory and pathology services. Clinsys is an integrated part of Jubilant's Drug Discovery and Development group, a strategic business division of Jubilant Organosys Ltd.

Jubilant, an integrated pharmaceutical industry services provider, is one of the largest custom research and manufacturing services (CRAMS) and drug discovery and development companies based out of India. The company has a presence across the pharmaceutical value chain for products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables (liquids and lyophilized) products, non-steriles (ointments, creams and liquid) and radiopharmaceuticals, drug discovery services, medicinal chemistry services, clinical research services, generic dosage forms and healthcare. Jubilant Organosys has geographically diversified manufacturing facilities at ten locations worldwide. Together, these help Jubilant cater to over 150 customers across more than 50 countries around the world.

Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.